typic
atyp
antipsychot
firstlin
treatment
schizophrenia
class
drug
univers
effect
seriou
side
effect
impact
complianc
antipsychot
drug
gener
target
dopamin
pathway
variat
research
schizophrenia
pathophysiolog
shift
away
strictli
dopaminecentr
focu
develop
new
pharmacotherapi
wane
field
inquiri
centuriesold
root
gain
traction
psychiatr
research
circl
may
repres
new
frontier
drug
discoveri
schizophrenia
forefront
investig
effort
immun
system
mani
compon
pathway
phenotyp
known
activ
engag
brain
studi
schizophrenia
reveal
intric
associ
environmentallydriven
immun
activ
concert
disrupt
genet
templat
consist
conduit
geneenvironment
milieu
gutbrain
axi
dysregul
gener
patholog
autoimmun
review
present
epidemiolog
biochem
evid
support
autoimmun
compon
schizophrenia
depict
gut
process
dysbiot
microbiom
sourc
perpetu
autoimmun
dysfunct
brain
within
framework
review
role
infecti
agent
inflamm
gut
dysbios
autoantibodi
propag
cn
patholog
neurotransmitt
receptor
hypofunct
complement
pathwaymedi
synapt
prune
review
new
pharmacotherapeut
horizon
novel
agent
direct
impact
patholog
condit
core
discours
understand
schizophrenia
etiolog
pathophysiolog
heterogen
thu
treatment
requir
individu
attent
diseas
state
variant
diagnos
object
biomark
schizophrenia
polygen
psychiatr
disord
defin
complex
posit
neg
cognit
symptom
posit
symptom
includ
delus
hallucin
wherea
neg
symptom
reflect
absenc
expect
respons
blunt
affect
anhedonia
loss
social
drive
individu
schizophrenia
also
often
suffer
cognit
difficulti
impact
organ
thought
process
concentr
task
complet
memori
apa
caus
schizophrenia
known
disord
thought
product
gene
environment
factor
interact
critic
neurodevelopment
time
point
demjaha
maccab
murray
european
network
nation
network
studi
geneenviron
interact
et
al
kavanagh
tansey
odonovan
owen
modino
et
al
nimgaonkar
prasad
chowdari
sever
yolken
schizophrenia
work
group
psychiatr
genom
tsuang
year
research
concentr
dopamin
receptor
pharmacolog
modul
subtyp
receptor
effect
treatment
case
schizophrenia
specif
although
dopamin
receptor
modifi
drug
effect
posit
symptom
mani
agent
rare
effect
neg
cognit
symptom
account
much
chronic
morbid
condit
research
focu
beyond
dopamin
receptor
broaden
includ
neurotransmitt
receptor
type
includ
serotonerg
cholinerg
glutamaterg
gabaerg
pathway
target
yet
discoveri
definit
caus
mechan
diseas
might
effect
guid
treatment
strategi
remain
elus
erhart
marder
carpent
marder
schizophrenia
current
treat
typic
atyp
antipsychot
older
typic
antipsychot
produc
sed
effect
close
target
dopamin
receptor
atyp
antipsychot
bind
dopamin
receptor
less
affin
addit
blockad
serotonin
receptor
seeman
secondgener
atyp
agent
gener
overcom
extrapyramid
motor
side
effect
associ
firstgener
typic
antipsychot
produc
metabol
side
effect
includ
diabet
mellitu
weight
gain
hyperlipidemia
crossley
constant
mcguir
power
ucok
gaebel
much
interag
interpati
variabl
gener
treatment
effect
reduc
posit
psychiatr
symptom
delus
hallucin
remain
signific
proport
patient
partial
fulli
resist
treatment
discontinu
medic
leucht
et
al
muller
furthermor
mention
mani
current
avail
antipsychot
fail
adequ
elicit
improv
neg
symptom
cognit
meyer
schwarz
muller
muller
differ
effect
side
effect
profil
metaanalysi
well
clinic
antipsychot
trial
intervent
effect
cati
cost
util
latest
antipsychot
drug
schizophrenia
studi
cutlass
trial
well
discuss
leucht
et
al
addit
pharmaceut
compani
downsiz
psychiatr
research
budget
current
appli
drug
though
flaw
still
effect
medic
avail
agent
also
becom
access
gener
bartfai
lee
technic
advanc
fuel
deep
sequenc
revolut
genom
wide
associ
studi
gwa
brought
identif
new
genet
loci
direct
treatment
research
effort
shed
light
new
mechan
guid
schizophrenia
diseas
pathophysiolog
one
except
focu
review
immun
system
immun
system
dysregul
schizophrenia
consist
replic
physiolog
target
encompass
gene
environment
interact
intern
schizophrenia
et
al
jone
mowri
pender
greer
kirch
knuesel
et
al
meyer
muller
rothermundt
arolt
bayer
sever
yolken
eaton
shi
et
al
stefansson
et
al
torrey
peterson
gwa
studi
identifi
chromosom
portion
hous
major
histocompat
complexhuman
leukocyt
antigen
mhchla
complement
loci
one
import
genet
suscept
region
schizophrenia
corvin
morri
intern
schizophrenia
et
al
sekar
et
al
shi
et
al
stefansson
et
al
mhchla
gene
famili
encod
cell
surfac
protein
bind
present
antigen
either
self
nonself
tcell
thu
dysfunct
thereof
predispos
suscept
infecti
diseas
graft
reject
cancer
autoimmun
complement
associ
interest
variat
gene
copi
number
may
caus
abnorm
synapt
prune
schizophrenia
presum
consequ
perturb
normal
neurodevelop
necessarili
intrins
abnorm
immun
sekar
et
al
genet
risk
allel
found
gwa
outsid
chromosom
region
also
involv
immun
pathway
network
pathway
analysi
subgroup
psychiatr
genom
genet
inform
coupl
decad
evid
environment
trigger
immun
risk
factor
newfound
function
brain
classic
peripher
immun
pathway
point
integr
immun
system
role
schizophrenia
among
dysregul
immun
condit
associ
schizophrenia
distinct
autoimmun
compon
review
autoimmun
compon
schizophrenia
mechan
comorbid
could
impact
central
nervou
system
cn
function
via
gutbrain
axi
overview
topic
model
fig
first
present
basic
tenet
autoimmun
context
relev
subsequ
evalu
autoimmun
schizophrenia
discuss
autoimmun
phenotyp
schizophrenia
term
risk
factor
diseas
includ
role
infect
peripher
central
inflammatori
state
gut
dysbios
presenc
autoantibodi
integr
discuss
mechan
contribut
relev
cn
patholog
includ
behavior
indic
sever
psychiatr
symptom
cognit
deficit
biochem
indic
complement
pathway
dysfunct
autoimmunerel
neurotransmitt
receptor
hypofunct
bring
light
new
therapeut
target
review
clinic
trial
alreadi
implement
test
efficaci
treatment
immun
pathway
schizophrenia
mainten
good
health
reli
immun
system
recogn
destroy
nonselfent
includ
bacteria
virus
foreign
antigen
well
remov
injur
mutat
selfent
apoptot
cell
environmentallyor
geneticallymodifi
nativ
protein
autoimmun
complex
condit
reflect
inabl
host
differenti
self
nonself
affect
individu
autoimmun
gener
indic
insuffici
establish
loss
immun
toler
toler
highli
regul
process
dualli
creat
central
peripher
central
toler
establish
primari
clonal
select
aim
elimin
immatur
selfreact
b
lymphocyt
thymu
bone
marrow
respect
matur
cell
distribut
system
selfreact
lymphocyt
escap
system
circul
peripher
toler
refer
inactiv
system
matur
autoreact
b
cell
typic
concentr
bodi
lymph
node
nonlymphoid
tissu
method
control
wayward
lymphocyt
includ
placement
anerg
state
remov
regulatori
cell
treg
murphi
traver
walport
janeway
theofilopoulo
kono
baccala
immun
toler
disrupt
autoimmun
diseas
ensu
condit
character
chronic
inflamm
autoantibodi
tissu
injuri
autoimmun
pathophysiolog
occur
system
system
lupu
erythematosu
organspecif
pattern
hashimoto
thyroiditisthyroid
type
diabet
mellituspancrea
rheumatoid
arthritisconnect
tissu
imbalanc
immun
system
overactiv
proinflammatori
effector
cell
outnumb
immunosuppress
treg
result
autoimmun
patholog
varieti
mechan
bring
imbal
one
suspect
trigger
autoimmun
infect
genet
suscept
peopl
murphi
et
al
theofilopoulo
et
al
recent
studi
danish
civil
registr
system
found
hospit
admiss
infect
risk
factor
autoimmun
disord
nielsen
kragstrup
deleuran
benro
infectionmedi
loss
toler
involv
polyclon
activ
autoreact
cell
molecular
mimicri
uncov
cryptic
antigen
creation
novel
selfreact
antigen
exampl
molecular
mimicri
antibodi
direct
infecti
agent
correspond
cell
becom
cross
reactiv
selfantigen
new
antigen
epitop
gener
pathogenderiv
protein
bind
host
cell
tissu
selfent
undergo
posttransl
pathogenelicit
modif
infect
also
break
sequest
tissuespecif
antigen
previous
quiescent
area
known
immunolog
privileg
gener
autoantibodi
initi
cellular
immun
machineri
clear
perceiv
invad
antigen
thu
lead
inflamm
tissu
damag
hypersensit
typifi
autoimmun
condit
murphi
et
al
theofilopoulo
et
al
autoantibodi
pathogen
bind
inactiv
cell
surfac
receptor
extracellular
molecul
format
immun
complex
collect
caus
tissu
damag
autoantibodi
gener
mother
also
potenti
affect
fetal
develop
part
antibodi
transfer
across
placenta
lleo
invernizzi
gao
podda
gershwin
possibl
autoantibodi
potenti
bind
import
brain
protein
may
underli
neuropsychiatr
symptom
gut
sourc
autoimmun
describ
later
low
grade
central
peripher
inflamm
emerg
risk
factor
develop
schizophrenia
bechter
bechter
et
al
sourc
inflamm
known
like
multipl
origin
differ
peopl
largest
immun
organ
bodi
gastrointestin
gi
tract
serv
critic
hub
regul
self
nonself
interact
via
gutassoci
lymphoid
tissu
galt
galt
function
convey
immun
toler
complex
commun
commens
microb
externallyderiv
dietari
product
host
cellular
machineri
simultan
protect
bodi
destruct
pathogen
danger
antigen
chistiakov
bobryshev
kozarov
sobenin
orekhov
dinan
cryan
sandhya
danda
sharma
scaria
wekerl
member
gut
microbiom
includ
bacteria
virus
archaea
fungi
compris
function
system
whose
goal
extract
metabol
absorb
nutrient
fuel
maintain
healthi
bodi
microb
downstream
product
howev
also
import
immunemodulatori
role
function
correctli
dynam
control
immun
respons
inflammatori
statu
gi
tract
breakdown
tryptophan
exampl
lead
broad
rang
kynureninerel
metabolit
function
proand
antiinflammatori
trigger
involv
excitatori
neurotransmiss
cervenka
agudelo
rua
bacteri
metabolit
structur
short
chain
fatti
acid
scfa
polysaccharid
moieti
function
divers
maintain
immun
homeostasi
proinflammatori
effect
dampen
antiinflammatori
treg
cellmedi
immunosuppress
wekerl
importantli
mani
microbi
metabolit
neuromodulatori
either
els
trigger
product
neurotransmitt
neuropeptid
dopamin
acetylcholin
gammaaminobutyr
acid
serotonin
brainderiv
neurotroph
factor
cryan
dinan
rieder
wisniewski
alderman
campbel
homeostat
microbiom
becom
imbalanc
dysbiot
mani
intrins
extrins
factor
includ
diet
pharmaceut
toxic
chemic
infecti
agent
even
genet
host
abegund
muhammad
bhatti
ali
sandhya
et
al
wu
et
al
dysbiosi
microbi
control
inflamm
shift
toward
proinflammatori
domin
suppress
antiinflammatori
treg
cell
chistiakov
et
al
hornig
wekerl
respons
increas
express
antimicrobi
protein
fig
model
autoimmun
phenotyp
oper
along
gutbrain
axi
schizophrenia
describ
main
text
infect
inflamm
gut
dysbios
autoantibodi
relat
measur
autoimmun
featur
schizophrenia
featur
contribut
permeabil
bloodgut
barrier
allow
transloc
gutbas
product
circul
interact
gut
product
neurotransmitt
receptor
locat
enter
nervou
system
may
one
sourc
autoantibodi
propag
especi
presenc
inflamm
system
lowgrad
inflammatori
state
perpetu
immun
system
activ
includ
complement
cytokin
product
pathway
turn
inflamm
may
contribut
compromis
bbb
allow
gutderiv
product
peripher
immun
factor
autoantibodi
access
brain
immun
dysfunct
suscept
infect
barrier
stabil
schizophrenia
may
genet
control
diagram
immun
cell
peyer
patch
system
circul
includ
macrophag
dendrit
cell
b
lymphocyt
lymphocyt
yy
refer
immunoglobulin
iga
igg
igm
downregul
inflammatori
pathway
increas
product
mucu
protect
epitheli
surfac
repair
damag
intestin
tissu
cellular
barrier
ismail
hooper
round
oconnel
mazmanian
smith
garrett
sommer
backh
commens
bacteria
invad
pathogen
breach
gi
mucosa
gutvasculatur
barrier
set
prime
gener
autoimmun
state
creation
inflammatori
environ
develop
foster
genesi
autoantibodi
microbi
dysbiosi
hypothes
role
etiolog
autoimmunebas
human
inflammatori
bowel
disord
includ
crohn
diseas
ulcer
coliti
powel
walker
talley
theofilopoulo
et
al
similarli
gut
constant
contact
foodderiv
antigen
set
toler
suffici
establish
also
trigger
autoimmun
toler
food
load
also
involv
microbi
mainten
epitheli
cellular
barrier
effici
digest
food
protein
immun
mediat
regulatori
dendrit
cell
steel
mayer
berin
gi
disord
autoimmun
mechan
direct
food
antigen
celiac
diseas
celiac
diseas
character
hypersensit
autoimmun
reaction
direct
wheat
gluten
antigen
combin
enzym
necessari
metabol
tissu
transglutaminas
individu
genet
predisposit
evidenc
specif
hladq
type
increasingli
psychiatr
comorbid
recogn
individu
autoimmun
gi
disord
fadgyasstanculet
buga
popawagn
dumitrascu
filipov
filipov
gupta
masand
kaplan
bhandari
hendrick
vaknin
eliakim
ackerman
steiner
vu
kushnir
cassel
gyawali
sayuk
convers
long
histori
data
demonstr
gi
inflamm
individu
psychiatr
disord
buscaino
hem
sever
prandovszki
castiglion
yolken
autoimmun
condit
brain
aris
via
vari
mean
injuryinduc
cytokin
releas
pathogenand
tumordirect
antibodi
crossreact
brain
protein
tcell
expos
previous
inaccess
brain
antigen
gene
confer
suscept
immun
dysfunct
pilli
zou
tea
dale
brilot
wekerl
cnsrelat
autoimmun
disord
includ
multipl
sclerosi
amyotroph
later
sclerosi
al
limbic
enceph
seizur
rasmussen
enceph
pediatr
autoimmun
neuropsychiatr
disord
associ
streptococc
infect
panda
antinmethyldaspart
nmda
receptor
enceph
dalmau
gei
grau
diamond
honig
mader
brimberg
volp
pilli
et
al
spite
vari
etiolog
mani
autoimmun
encephalopathi
similarli
character
inflammatori
state
presenc
antibodi
direct
brain
structur
neuron
surfac
receptor
synapt
protein
dalmau
et
al
diamond
et
al
newman
et
al
research
field
progress
intric
extens
role
peripher
immun
within
cn
becom
better
understood
appreci
cn
long
consid
immuneprivileg
organ
thu
impervi
process
involv
peripher
immun
cell
structur
protect
come
blood
brain
barrier
bbb
endotheli
cellvascular
interfac
reinforc
tight
junction
protein
astrocyt
process
thought
prevent
peripher
immun
factor
cell
enter
brain
recent
data
bring
question
contenti
issu
regard
requir
integr
bbb
compromis
order
autoimmun
featur
affect
cn
bbb
permeabl
would
presum
requir
autoantibodi
gener
peripher
activ
brain
well
cn
entri
inflammatori
molecul
immun
entiti
pollak
et
al
becom
evid
subset
lymphocyt
abl
gain
access
take
resid
cn
spite
intact
bbb
b
cell
may
becom
activ
presenc
microbi
infect
wekerl
perceiv
impenetr
structur
immun
barrier
brain
disput
discoveri
lymphat
vessel
line
dural
sinus
connect
csf
deep
cervic
lymph
node
vessel
cell
suggest
conduit
cn
lymph
node
provid
evid
cn
site
access
immunosurveil
louveau
et
al
nevertheless
inflamm
render
bbb
permeabl
therefor
like
numer
autoimmun
condit
acceler
bbb
inappropri
breach
hammer
et
al
pathogen
infect
interestingli
germfre
experiment
mous
studi
absenc
gut
microb
associ
dysfunct
bbb
alter
myelin
cortic
neuron
cognit
deficit
behavior
chang
blander
longman
iliev
sonnenberg
arti
sharon
sampson
geschwind
mazmanian
wide
rang
type
antigen
bring
similar
immun
effect
suggest
immun
system
respons
dysregul
thereof
rather
specif
pathogen
food
exposur
contribut
neuropsychiatr
diseas
immun
system
respons
take
form
adapt
immun
antigenspecif
respons
elicit
machineri
gener
immunolog
memori
clonal
select
lymphocyt
immun
respons
also
innat
form
character
less
specif
immedi
cellular
defens
clear
invad
pathogen
antigen
identifi
foreign
murphi
et
al
complement
pathway
bridg
innat
adapt
immun
initi
activ
form
immun
complex
aid
clear
foreign
antigen
damag
cell
autoantigen
circul
defect
complement
pathway
lead
increas
suscept
infect
autoimmun
disord
complement
deficit
result
accumul
apoptot
debri
immun
complex
deposit
inflamm
tissu
damag
linger
apoptot
wast
sourc
autoantigen
especi
inflamm
genet
suscept
individu
subsequ
cell
activ
lead
autoreact
b
cell
autoantibodi
walport
walport
system
lupu
erythematosu
sle
exampl
autoimmun
diseas
character
system
autoimmun
symptom
result
tissu
injuri
multipl
organ
due
high
level
immun
complex
deposit
sle
associ
alter
level
multipl
complement
protein
includ
firstlin
antigen
recognit
protein
form
immun
complex
antigen
bound
antibodi
found
downstream
classic
pathway
also
part
pampor
dampiniti
lectin
pathway
case
involv
enzymat
reaction
assembl
eventu
activ
membran
attack
complex
ballanti
et
al
martin
blom
walport
walport
intriguingli
recent
discoveri
last
decad
peripher
complement
pathway
found
activ
brain
describ
rodent
model
complement
protein
function
synaps
format
elimin
neuron
develop
well
respons
presenc
brain
pathogen
adult
biala
steven
boulang
fourgeaud
boulang
hong
et
al
lui
et
al
presumey
biala
carrol
ransohoff
steven
schafer
et
al
stephan
et
al
steven
et
al
vasek
et
al
subsequ
identif
polymorph
genet
risk
factor
schizophrenia
sekar
et
al
potenti
import
implic
autoimmun
studi
schizophrenia
may
repres
nexu
molecular
pathway
genet
environment
etiolog
disord
reconcil
nimgaonkar
et
al
respect
schizophrenia
time
exposur
infecti
diseas
matern
gener
antibodi
prenat
earli
postnat
period
topic
focu
numer
investig
result
gener
support
neurodevelopment
hypothes
schizophrenia
etiolog
allswed
buka
yolken
torrey
cannon
blomstrom
et
al
brown
cohen
greenwald
susser
buka
et
al
ellman
yolken
buka
torrey
cannon
karlsson
et
al
mortensen
et
al
pedersen
steven
pedersen
norgaardpedersen
mortensen
sever
gressitt
buka
cannon
yolken
xiao
et
al
precis
activ
complement
respons
matern
antibodi
load
implic
mechan
inappropri
fetal
activ
synapt
prune
etiolog
pathway
schizophrenia
describ
point
autoimmun
materi
multipl
mechan
reflect
bodi
failur
accur
recogn
cellular
makeup
emerg
data
indic
patholog
may
well
impact
brain
similar
dysregul
adapt
cellular
immun
increasingli
demonstr
schizophrenia
suggest
disord
although
classic
autoimmun
diseas
may
share
common
potenti
treatabl
physiolog
featur
earli
record
examin
associ
autoimmun
disord
schizophrenia
document
discoveri
invers
correl
preval
rheumatoid
arthriti
schizophrenia
relationship
also
recent
replic
chen
et
al
eaton
hayward
ram
gorwood
et
al
sellgren
frisel
lichtenstein
landen
askl
trevathan
tatum
investig
includ
recent
largescal
birth
registri
studi
found
posit
associ
array
autoimmun
disord
includ
multipl
sclerosi
system
lupu
erythematosu
autoimmun
thyrotoxicosi
autoimmun
hepat
psoriasi
diagnosi
schizophrenia
psychosi
chen
et
al
eaton
et
al
gilvarri
et
al
wright
et
al
addit
also
found
histori
infect
contribut
elev
risk
autoimmun
disord
develop
schizophrenia
benro
et
al
similarli
histori
infect
famili
member
schizophrenia
also
significantli
elev
risk
develop
autoimmun
diseas
recent
analysi
registri
data
indic
combin
histori
infect
exposur
antiinfect
agent
antibiot
augment
risk
develop
schizophrenia
kohler
et
al
like
certain
case
autoimmun
disord
schizophrenia
may
result
geneticallyencod
insuffici
overact
immun
respons
trigger
exposur
environment
factor
infect
data
studi
microbiom
also
suggest
genesi
autoimmun
occur
least
part
gut
dysbiot
de
oliveira
leit
higuchi
gonzaga
mariano
fung
olson
hsiao
thaiss
zmora
levi
elinav
intestin
origin
autoimmun
also
reconcil
numer
risk
factor
develop
schizophrenia
turn
support
exist
gutbrain
connect
similarli
faulti
genet
templat
perhap
involv
variat
mutat
mhc
hla
complement
loci
autoimmun
disord
schizophrenia
may
result
dysregul
immun
respons
pathogen
wide
array
environmentallyand
endogenouslyderiv
antigen
reaction
antigen
provok
inflamm
hallmark
characterist
autoimmun
state
often
observ
peopl
schizophrenia
bechter
dickerson
et
al
fillman
et
al
miller
buckley
seabolt
mellor
kirkpatrick
interest
respect
brain
disord
mani
compon
complement
pathway
part
inflammationgener
trajectori
also
mention
newlydiscov
function
synaps
format
prune
autoantibodi
also
prime
perpetu
autoimmun
inflammatori
state
autoantibodi
direct
import
brain
protein
neurotransmitt
receptor
neuron
function
greatli
compromis
section
review
evid
support
pathogen
exposur
inflamm
gutbrain
axi
autoantibodi
autoimmun
phenotyp
schizophrenia
long
histori
research
support
infect
process
lead
autoimmun
disord
ercolini
miller
nielsen
et
al
therefor
surpris
exposur
pathogen
posit
autoimmun
risk
factor
develop
schizophrenia
hornig
torrey
peterson
among
document
infecti
diseas
agent
type
infect
associ
schizophrenia
protozoan
toxoplasma
gondii
influenza
virus
cytomegaloviru
human
herpesvirus
borna
diseas
viru
endogen
retrovirus
coronavirus
urinari
tract
infect
chlamydophilla
candida
yeast
infect
aria
et
al
hornig
karlsson
et
al
karlsson
schroder
bachmann
bottmer
yolken
lewek
et
al
miller
et
al
sever
et
al
torrey
et
al
torrey
bartko
lun
yolken
torrey
bartko
yolken
studi
pathogen
exposur
associ
decreas
cognit
function
progress
gray
matter
loss
prasad
et
al
prasad
watson
dickerson
yolken
nimgaonkar
schretlen
et
al
sever
gressitt
et
al
shirt
et
al
watson
et
al
yolken
torrey
lieberman
yang
dickerson
focu
review
identifi
autoimmun
condit
peopl
schizophrenia
direct
toward
identif
new
treatment
howev
note
also
larg
literatur
base
prenat
exposur
specif
microb
infecti
diseas
process
risk
factor
futur
develop
schizophrenia
brown
et
al
brown
begg
et
al
brown
derkit
brown
hooton
et
al
buka
et
al
ellman
et
al
est
mcallist
mortensen
et
al
pedersen
et
al
xiao
et
al
perhap
consist
replic
find
pathogen
exposur
associ
diagnosi
schizophrenia
involv
parasit
pathogen
gondii
aria
et
al
monro
buckley
miller
torrey
et
al
torrey
et
al
recent
year
connect
regard
context
gondii
gut
pathogen
show
signific
associ
gutbas
antigen
inflammatori
process
peopl
schizophrenia
sever
yolken
eaton
inde
gondii
use
routin
experiment
rodent
model
inflammatori
bowel
diseas
craven
et
al
grainger
et
al
hand
et
al
heimesaat
et
al
thu
inflammationgener
neurotrop
parasit
abl
permeabil
endotheli
cell
barrier
gondii
uniqu
equip
patholog
impact
brain
directli
result
glial
cell
activ
indirectli
via
facilit
entri
system
immun
gutderiv
factor
cn
mous
model
demonstr
extens
gondiigener
complement
activ
brain
vicin
parasit
proxim
synaps
xiao
et
al
recent
translat
studi
found
parallel
increas
mice
human
autoantibodi
direct
nmda
receptor
expos
gondii
correspond
elev
surrog
marker
compromis
bloodgutbarri
bbb
kannan
et
al
result
studi
also
document
effect
parasit
exposur
clinic
endpoint
decreas
cognit
suicid
behavior
sever
psychot
symptom
esshili
et
al
hamdani
et
al
kannan
et
al
lindgren
et
al
schizophrenia
classic
autoimmun
disord
also
classic
inflammatori
disord
schizophrenia
detect
inflamm
ascrib
lowgrad
natur
peripher
central
inflammatori
state
measur
use
varieti
biomark
differ
research
lab
bechter
catt
wong
fillman
fung
shannon
weickert
dickerson
et
al
fillman
et
al
fillman
et
al
fillman
sinclair
fung
webster
shannon
weickert
kirkpatrick
miller
miller
et
al
muller
sever
et
al
case
sourc
inflamm
studi
known
evid
form
proand
antiinflammatori
cytokin
dysregul
disrupt
tryptophan
kynurenin
metabol
exposur
microbi
pathogen
antigen
food
hypersensit
complement
activ
postmortem
patholog
brain
imag
larg
metaanalysi
cytokin
schizophrenia
provid
strong
evid
upregul
proinflammatori
cytokin
associ
schizophrenia
particularli
ifngamma
tnfalpha
compar
control
miller
et
al
interestingli
patient
receiv
antipsychot
medic
show
significantli
decreas
level
ifn
gamma
suggest
immunosuppress
effect
drug
effect
previous
demonstr
investig
haloperidol
clozapin
leykin
mayer
shinitzki
muller
simultan
increas
receptor
schizophrenia
howev
suggest
cytokin
network
dysregul
necessarili
uniformli
proinflammatori
direct
note
earlier
complement
activ
part
bodi
inflammatori
defens
respons
culmin
launch
membran
attack
complex
alter
peripher
complement
compon
schizophrenia
includ
although
studi
report
consist
find
arakelyan
et
al
boyajyan
khoyetsyan
tsakanova
sim
kucharskamazur
et
al
mayilyan
mayilyan
weinberg
sim
santo
soria
moura
gubert
ceres
gama
kapczinski
also
upregul
central
postmortem
human
brain
sampl
show
increas
rna
express
schizophrenia
compar
control
sekar
et
al
note
polymorph
identifi
confer
genet
suscept
schizophrenia
copi
number
variat
impact
level
gene
express
mayilyan
mayilyan
dodd
boyajyan
soghoyan
sim
sekar
et
al
preliminari
evid
studi
twin
schizophrenia
implic
peripher
express
complement
gene
cortic
thin
allswed
et
al
centrallyderiv
complement
activ
implic
brain
biochemistri
synapt
prune
chronic
peripher
inflamm
also
brain
effect
associ
cognit
impair
schizophrenia
bulzacka
et
al
posit
next
section
logic
possibl
sourc
inflamm
deriv
gut
microbiom
imbalanc
imbal
may
caus
transloc
microb
microbi
product
antigen
food
product
across
gut
vasculatur
instig
low
level
inflamm
autoimmunegener
potenti
sever
yolken
eaton
discuss
earlier
imbalanc
gi
environ
prime
venu
product
autoantigen
lead
autoimmun
disord
often
replic
tie
schizophrenia
fact
celiac
diseas
baldwin
bender
dohan
dohan
dohan
eaton
et
al
graff
handford
discuss
earlier
peopl
celiac
diseas
intoler
wheat
gluten
ingest
caus
bodi
launch
autoimmun
attack
perceiv
novel
antigen
complex
gluten
bound
cellderiv
tissu
transglutaminas
small
intestin
alaedini
green
green
et
al
guandalini
assiri
gluten
antibodi
also
shown
bind
synapserel
brain
protein
alaedini
et
al
briani
et
al
hadjivassili
et
al
connect
gluten
exposur
psychiatr
disord
first
hypothes
fc
dohan
observ
psychiatr
hospit
rate
europ
strongli
correl
amount
wheat
consumpt
vari
consider
immedi
world
war
ii
dohan
dohan
sinc
numer
studi
metaanalys
examin
associ
food
antigen
schizophrenia
vari
result
cascella
et
al
dickerson
et
al
jin
et
al
mclean
wilson
st
clair
mustard
wei
reichelt
landmark
reichelt
stensrud
samaroo
et
al
sever
et
al
studi
gluten
antibodi
profil
correl
measur
gi
inflamm
sever
et
al
interestingli
recent
clinic
studi
antigliadin
antibodi
found
predict
brain
inflamm
measur
via
proton
magnet
reson
spectroscopi
rowland
et
al
celiac
diseas
mark
strong
hla
associ
pathogen
autoantibodi
gener
celiac
diseas
repres
classic
interact
gene
environ
immunolog
hardi
tyedin
similar
oper
mechan
may
present
certain
peopl
schizophrenia
suffer
gluten
sensit
inflammatori
bowel
diseas
among
autoimmun
disord
found
increas
frequenc
schizophrenia
gupta
et
al
sever
prandovszki
et
al
likewis
indic
emerg
data
peopl
diagnos
gi
disord
increas
rate
psychiatr
symptom
fadgyasstanculet
et
al
filipov
filipov
gupta
et
al
vaknin
et
al
vu
et
al
gi
disturb
relat
mental
ill
record
earli
first
second
centuri
hippocr
later
galen
advoc
practic
treat
gut
order
improv
brain
function
sever
prandovszki
et
al
sinc
search
physiolog
basi
gutbrain
connect
resurfac
period
particularli
start
centuri
interest
topic
current
alltim
high
histor
preced
gi
studi
mental
ill
import
present
misbelief
gi
comorbid
primarili
result
medic
intestin
motil
impair
anticholinerg
side
effect
antipsychot
gi
dysfunct
attribut
medic
document
numer
studi
includ
predat
introduct
antipsychot
medic
occur
examin
variou
girel
biomark
patient
sever
prandovszki
et
al
preantipsychot
era
studi
post
mortem
tissu
report
schizophrenia
group
extens
bowel
inflamm
buscaino
hem
studi
food
antigen
exposur
yeast
exposur
bacteri
dysbiosi
entiti
contribut
girel
inflamm
individu
schizophrenia
sever
et
al
sever
et
al
sever
gressitt
et
al
parallel
studi
antipsychot
individu
support
biomark
pattern
specif
diseas
state
result
immun
effect
drug
biomark
studi
also
document
transloc
gutbas
product
food
peptid
microbi
product
system
circul
increas
rate
peopl
schizophrenia
compar
control
discuss
earlier
known
gi
inflamm
produc
environ
deleteri
effect
gut
vasculatur
barrier
found
evid
compromis
endotheli
barrier
patholog
gut
cn
associ
schizophrenia
peopl
intact
endotheli
barrier
gutderiv
food
antigen
antibodi
found
peripher
serum
associ
found
central
csf
peopl
schizophrenia
found
strong
correl
serum
csf
antibodi
present
control
individu
without
psychiatr
disord
gutderiv
inflamm
product
sourc
gut
microbiom
balanc
gut
microbiom
yet
extens
studi
schizophrenia
initi
deep
sequenc
studi
microbi
taxa
suggest
alter
pattern
divers
associ
diseas
compar
control
castronallar
et
al
schwarz
et
al
yolken
et
al
oropharyng
microbiom
speci
lactic
acid
bacteria
lactobacilli
bifidobacterium
known
regul
chronic
inflamm
abund
schizophrenia
compar
control
castronallar
et
al
interestingli
level
viral
phage
lactobacillu
phage
phiadh
also
alter
schizophrenia
correl
level
correspond
bacteri
host
lactobacillu
gasseri
studi
fecal
microbiom
also
point
toward
elev
lactobacillu
bacteria
individu
first
episod
psychosi
compar
control
importantli
indic
level
relat
sever
psychot
symptom
respons
treatment
schwarz
et
al
studi
microbiom
well
document
microbi
transloc
collect
indic
gut
dysbios
put
preval
schizophrenia
dickerson
sever
yolken
studi
aim
elucid
function
consequ
microbi
dysbiosi
cn
endpoint
psychiatr
symptom
cognit
treatment
resist
desper
need
thu
inflamm
intestin
tract
associ
compromis
gutblood
cytolog
barrier
vari
implic
peopl
psychiatr
disord
may
coexist
autoimmun
condit
microbi
relat
product
bloodstream
lead
system
immun
activ
potenti
patholog
state
may
alreadi
aggrav
individu
geneticallyencod
immun
dysfunct
endotheli
barrier
permeabl
impact
givasculatur
interfac
provid
mean
gutderiv
product
might
penetr
bloodbrain
barrier
cytolog
architectur
structur
similar
faulti
barrier
may
particularli
import
autoantibodi
gener
inflammatori
gut
environ
abl
cross
compromis
bbb
intestin
system
flux
may
predispos
autoimmun
mean
wide
array
neurotransmitt
target
found
enter
nervou
system
ident
found
brain
understand
role
autoantibodi
reactiv
brain
protein
longstand
subject
studi
examin
autoimmun
psychiatr
disord
boehm
cottrel
dohan
hillegass
durel
archer
fessel
fessel
glebov
gurevich
heath
heath
krupp
heath
krupp
byer
liljekvist
heath
krupp
byer
liljekvist
jone
et
al
kirch
lehmannfaciu
mellsop
whittingham
ungar
stamboliev
stoimenov
recent
metaanalysi
record
signific
elev
differ
autoantibodi
person
schizophrenia
compar
control
ezeok
mellor
buckley
miller
schizophrenia
autoantibodi
direct
number
brain
protein
examin
particularli
exclus
target
neurotransmitt
receptor
cholinerg
muscarin
receptor
nicotin
acetylcholin
receptor
dopamin
receptor
muopioid
receptor
serotonin
receptor
ampa
receptor
glutam
receptor
gammaaminobutyr
acid
gaba
receptor
glutam
acid
decarboxylas
gad
potassium
channel
receptor
deakin
lennox
zandi
ezeok
et
al
jone
et
al
masdeu
et
al
studi
also
highlight
brainrel
entiti
may
regul
autoantibodi
includ
human
endogen
retrovirus
herv
cardiolipin
dna
histon
mitochondria
rational
studi
neurotransmitt
receptor
base
idea
autoantibodi
bind
suppress
activ
otherwis
block
contribut
receptor
hypofunct
note
cell
surfac
target
neurotransmitt
receptor
presum
access
intracellular
target
dna
mitochondria
nmda
receptor
hypofunct
longheld
hypothesi
schizophrenia
etiolog
evid
blockag
healthi
peopl
precipit
symptom
schizophrenia
gilmour
et
al
posit
associ
nmda
receptor
autoantibodi
schizophrenia
howev
uniformli
replic
suggest
possibl
autoantibodi
presenc
may
sole
diseas
associ
ando
et
al
castillogomez
et
al
dahm
et
al
de
witt
et
al
deakin
et
al
dickerson
et
al
haussleit
et
al
masdeu
et
al
masopust
et
al
pearlman
najjar
pollak
mccormack
peakman
nicholson
david
rhoad
guirgi
mcknight
duchemin
steiner
et
al
steiner
et
al
timucin
ozdemir
parlak
zandi
et
al
exampl
put
pathogen
antinmda
receptor
antibodi
braindirect
antibodi
found
present
multipl
nonpsychiatr
control
group
castillogomez
et
al
glass
et
al
autoantibodi
presenc
control
may
also
signific
possibl
autoantibodi
may
serv
regulatori
function
addit
possibl
twohit
hypothesi
effect
autoantibodi
pathogen
access
bbb
requir
discuss
respect
parasit
gondii
infect
may
potent
agent
barrier
permeabil
autoantibodi
gener
kannan
et
al
review
focus
gondii
perpetr
autoimmun
infecti
diseas
agent
may
also
produc
autoantibodi
includ
hiv
arboleya
et
al
nicotin
acetylcholin
receptor
repres
interest
autoimmun
target
introduc
put
contribut
entericallyloc
vagu
nerv
thu
anoth
gutbrain
connect
vagu
nerv
carri
inform
enter
nervou
system
cn
hypothes
certain
subset
patient
vagu
nerv
stimul
control
peripher
central
inflamm
modul
nicotin
acetylcholin
receptor
subtyp
corsizuelli
et
al
thu
autoantibodi
present
receptor
sever
studi
schizophrenia
found
chandley
miller
kwasigroch
wilson
miller
mukherje
et
al
suppress
inflamm
dysregul
antiinflammatori
modul
may
ensu
set
studi
implic
enter
nervou
system
rich
autoantibodi
sourc
relev
brain
target
enter
nervou
system
equip
much
extens
array
neurotransmitt
receptor
found
brain
final
respect
autoantibodi
address
time
exposur
potenti
patholog
agent
particularli
fetu
larg
repertoir
work
rodent
document
role
matern
immun
activ
detriment
fetal
brain
biochemistri
brown
derkit
est
mcallist
among
pathway
studi
complement
found
elev
peripher
well
central
follow
infect
mother
han
zhang
hashimoto
result
human
studi
also
support
neurodevelopment
role
matern
immun
activ
confer
risk
develop
schizophrenia
psychosi
adult
offspr
allswed
et
al
brown
derkit
est
mcallist
larg
high
profil
studi
swedish
birth
registri
demonstr
elev
gluten
antibodi
mother
whose
children
went
develop
psychosi
adult
previous
found
bound
form
immun
complex
gluten
increas
rate
schizophrenia
compar
control
examin
matern
level
birth
cohort
nation
collabor
perinat
project
also
found
elev
level
mother
whose
children
went
develop
psychosi
sever
et
al
studi
matern
level
significantli
correl
gluten
adenoviru
rodent
model
matern
immun
activ
elev
prefront
cortex
adult
offspr
mother
treat
poli
c
pregnanc
placent
transfer
matern
antibodi
primari
mean
confer
offspr
immun
inde
recent
work
autoantibodi
contactinassoci
proteinlik
protein
import
brain
develop
isol
mother
children
neurodevelopment
disord
variat
brimberg
et
al
model
antibodi
cap
mice
pregnanc
result
offspr
signific
microgli
activ
synapt
loss
structur
insuffici
cortex
hippocampu
behavior
abnorm
brimberg
et
al
thu
presenc
matern
autoantibodi
import
brain
protein
includ
complement
neurotransmitt
receptor
may
tangibl
threat
develop
fetu
studi
comorbid
physiolog
condit
present
individu
schizophrenia
offer
clue
cellular
pathway
defici
could
evalu
treatment
describ
review
immun
system
mani
complex
dysregul
result
autoimmun
state
immun
network
repres
novel
group
therapeut
target
may
relev
studi
brain
disord
intricaci
immun
system
polygen
polyenvironment
heterogen
schizophrenia
disord
howev
reinforc
likelihood
one
treatment
approach
relev
everi
patient
critic
preidentifi
subset
patient
experienc
specif
autoimmun
characterist
diagnos
comorbid
appropri
biomark
effect
individu
treatment
approach
design
implement
addit
import
develop
biomark
treatment
respons
side
effect
present
time
treatment
describ
best
consid
potenti
adjunct
current
employ
antipsychot
section
review
evid
support
vari
therapeut
approach
treat
autoimmunederiv
abnorm
schizophrenia
given
overlap
mechan
treat
patholog
condit
certain
therapeut
approach
may
appropri
manag
multipl
autoimmun
condit
minocyclin
tetracyclin
antibiot
evalu
sever
clinic
trial
adjunct
treatment
antipsychot
associ
improv
certain
psychiatr
symptom
cognit
chaudhri
et
al
kelli
et
al
levkovitz
et
al
liu
et
al
miyaoka
et
al
sever
metaanalys
support
safeti
efficaci
solmi
et
al
xiang
et
al
interestingli
effect
minocyclin
schizophrenia
may
sole
result
direct
antimicrobi
activ
minocyclin
may
also
inhibit
detriment
effect
microgli
activ
includ
free
radic
gener
impair
adult
neurogenesi
mattei
et
al
antibiot
azithromycin
dcycloserin
test
small
studi
mix
result
remain
candid
followup
studi
biomark
avail
identifi
appropri
patient
goff
schade
paulu
mechan
action
dcycloserin
may
especi
inform
schizophrenia
hypothes
link
dysfunct
nmda
receptor
dcycloserin
known
partial
agonist
glycin
modulatori
site
receptor
goff
mcbain
kleckner
wyrick
dingledin
experiment
data
also
need
determin
role
antibiot
benefici
detriment
modul
gut
microbiota
thu
gutbrain
axi
sever
antivir
agent
test
adjunct
therapi
includ
valacyclovir
variou
patient
popul
prescreen
seroposit
certain
virus
mix
find
first
studi
signific
improv
psychiatr
symptom
valacyclovir
evid
individu
seroposit
cytomegaloviru
seroposit
herpesvirus
dickerson
boronow
stall
origoni
yolken
placebocontrol
followup
studi
differ
psychiatr
symptom
evid
two
treatment
group
clinic
trial
date
demonstr
chang
psychiatr
symptom
cognit
therapi
aim
treat
gondii
infect
chorlton
although
antimalari
compound
involv
artemisinin
deriv
show
signific
effect
psychiatr
endpoint
two
studi
wang
et
al
reduct
antibodi
direct
food
antigen
gluten
found
treatment
group
compar
placebo
inflamm
document
mani
individu
schizophrenia
creat
physiolog
state
predispos
suscept
individu
autoimmun
possibl
antiinflammatori
pharmacotherapi
may
benefici
meyer
et
al
agent
therapeut
potenti
includ
inhibitor
nacetylcystein
statin
use
monoclon
antibodi
cytokin
blocker
miller
buckley
muller
acetylsalicyl
acid
aspirin
inhibitor
shown
significantli
lower
posit
psychiatr
score
smaller
studi
well
metaanalys
laan
et
al
nitta
et
al
sommer
et
al
inhibitor
celecoxib
administ
adjunct
antipsychot
agent
also
result
improv
symptomscognit
compar
risperidon
alon
sever
studi
trial
although
benefit
observ
earlier
diseas
stage
akhondzadeh
et
al
marini
et
al
muller
muller
et
al
muller
et
al
howev
benefit
celecoxib
confirm
two
metaanalys
antiinflammatori
agent
nitta
et
al
sommer
et
al
appear
efficaci
improv
psychot
symptom
firstepisod
schizophrenia
third
metaanalysi
oxid
stress
evidenc
shift
balanc
favor
proversu
antioxid
result
disrupt
redox
signal
phenotyp
increasingli
associ
schizophrenia
cuenod
hensch
biomark
oxid
stress
glutathion
glutathion
peroxidas
superoxid
dismutas
thought
reflect
disrupt
alter
biomark
record
schizophrenia
psychosi
coughlin
et
al
coughlin
et
al
langbein
et
al
nucifora
et
al
zenigraiff
et
al
zhang
catt
shannon
weickert
nacetylcystein
precursor
glutathion
potent
antioxid
well
antiinflammatori
properti
found
variat
significantli
improv
psychiatr
symptom
sever
cognit
varieti
psychiatr
disord
includ
schizophrenia
berk
et
al
chen
chibnal
nasrallah
conu
et
al
farokhnia
et
al
minarini
et
al
nitta
et
al
sommer
et
al
zheng
et
al
nacetylcystein
interest
multipl
effect
cytokin
gener
remov
role
glutamaterg
dopaminerg
neurotransmiss
bumb
en
lewek
sommer
et
al
adjunct
pravastatin
cholesterol
lower
medic
found
significantli
lower
posit
psychiatr
score
baselin
week
although
benefit
maintain
week
vincenzi
et
al
trend
toward
benefit
symptom
reduct
also
observ
simvastatin
serotonin
receptor
antagonist
ondansestron
chaudhri
et
al
adjunct
treatment
anoth
statin
lovastatin
associ
improv
psychiatr
symptom
ghanizadeh
rezae
dehbozorgi
berk
akhondzadeh
metaanalysi
adjunct
statin
therapi
schizophrenia
indic
favor
improv
psychiatr
symptom
associ
treatment
shen
et
al
base
result
sever
small
studi
potenti
cytokin
target
might
promis
schizophrenia
includ
monoclon
antibodi
direct
receptor
tocilizumab
tumor
necrosi
factor
infliximab
miller
buckley
peopl
inflammatori
bowel
diseas
exampl
antitumor
necrosi
aid
reduct
mucos
inflamm
pach
rogler
felley
sever
trial
monoclon
antibodi
treatment
schizophrenia
underway
inflamm
schizophrenia
may
relat
dysregul
complement
system
coupl
complement
function
brain
make
pathway
prime
candid
har
adjunct
treatment
schizophrenia
therapeut
strategi
focus
inhibit
complement
activ
primarili
success
target
termin
pathway
barnum
barnum
barnum
barnum
provid
comprehens
review
progress
histori
target
complement
pathway
use
small
molecul
sirna
inhibitor
antibodi
antibodi
eculizumab
exampl
favor
safeti
effect
result
manag
indic
hillmen
et
al
end
result
block
format
membran
attack
complex
complement
pathway
upstream
would
remain
intact
target
develop
complement
inhibitor
autoimmun
progress
morgan
harri
schizophrenia
import
understand
precis
complement
compon
dysfunct
peripher
brain
order
effect
complementbas
treatment
design
oper
rational
correct
microbi
imbal
decreas
gut
inflamm
resolv
sourc
autoimmun
elimin
sequenc
patholog
compromis
barrier
permeabl
inappropri
immun
activ
way
progress
may
made
toward
therapeut
improv
psychiatr
symptom
cognit
sever
approach
thu
fall
categori
includ
use
prebiot
short
chain
fatti
acid
scfa
probiot
fecal
transplant
variou
combin
thereof
studi
object
perform
experiment
rodent
model
result
number
human
clinic
studi
also
show
promis
prebiot
special
plant
product
use
stimul
colon
intestin
tract
benefici
bacteria
metabol
host
scfa
metabolit
gener
ferment
fiber
gut
microb
scfa
modul
inflammatori
metabol
pathway
like
abl
cross
bbb
joseph
depp
shih
cadenhead
schmidschonbein
joseph
et
al
propos
diet
enrich
fiber
conjunct
scfa
mediterranean
diet
might
improv
immun
outcom
dysregul
schizophrenia
intestin
permeabl
may
also
improv
scfa
propion
butyr
polyunsatur
fatti
acid
fatti
acid
michielan
dinca
satogami
takahashi
yamada
ukai
shinosaki
show
reduc
level
blood
associ
signific
cognit
impair
individu
schizophrenia
number
trial
supplement
schizophrenia
neg
chen
chibnal
nasrallah
fenton
dickerson
boronow
hibbeln
knabl
qiao
et
al
satogami
et
al
result
rodent
studi
show
diet
enrich
microbi
metabolit
acet
butyr
increas
regulatori
cell
densiti
improv
gut
barrier
cohes
reduc
diabetogen
cytokin
marino
et
al
probiot
supplement
contain
live
benefici
gut
bacteria
sometim
yeast
administ
rational
microorgan
reestablish
balanc
microbiom
probiot
evalu
schizophrenia
three
analys
placebocontrol
studi
found
probiot
lactobacillu
rhammosu
strain
gg
bifidobacterium
anim
subsp
lacti
strain
given
per
day
improv
gi
symptom
alter
immun
intestin
epitheli
pathway
associ
decreas
antibodi
level
opportunist
pathogen
candida
albican
dickerson
et
al
sever
gressitt
et
al
tomasik
yolken
bahn
dickerson
analys
probiot
deliv
benefit
improv
residu
psychot
symptom
interestingli
impact
psychiatr
symptom
probiot
suggest
evid
c
albican
infect
fecal
transplant
also
involv
reprim
dysfunct
gut
microbiom
live
bacteria
healthi
donor
usual
perform
purpos
treat
clostridium
difficil
infect
also
experiment
use
autoimmun
diseas
shown
promis
inflammatori
bowel
diseas
millan
laffin
madsen
weingarden
vaughn
case
report
also
describ
benefit
treat
autism
parkinson
diseas
multipl
sclerosi
chronic
fatigu
syndrom
evrensel
ceylan
dietari
modif
avoid
high
anim
protein
high
carbohydr
content
essenti
improv
microbiom
composit
toward
healthi
balanc
statovci
aguilera
macsharri
melgar
dietari
avoid
gluten
standard
treatment
celiac
diseas
gluten
intoler
glutenfre
diet
peopl
schizophrenia
fact
found
associ
decreas
preval
thyroid
autoantibodi
toscano
et
al
ventura
et
al
pharmacolog
agent
develop
treat
celiac
diseas
includ
gluten
degrad
enzym
anpep
clinic
trial
show
promis
reduc
symptom
gluten
tcell
respons
mitea
et
al
siegel
et
al
tyedin
et
al
zonulin
inhibitor
larazotid
also
develop
block
gluten
transit
across
intestin
barrier
demonstr
improv
symptom
fewer
autoantibodi
reduc
proinflammatori
state
patient
celiac
diseas
parzanes
et
al
mice
endogen
serin
proteas
inhibitor
elafin
shown
normal
inflamm
restor
intestin
barrier
function
galipeau
et
al
compound
sevelam
avail
treat
symptom
chronic
kidney
diseas
bind
bacteri
protein
prevent
transloc
gut
circul
kristoff
et
al
compound
begin
stage
preclin
develop
thu
requir
extens
safeti
efficaci
regulatori
test
clinic
trial
consid
therapeut
strategi
diminish
effect
autoantibodi
involv
plasmapheresi
remov
antibodi
system
circul
immunosuppress
offset
actual
product
antibodi
plasmapheresi
schizophrenia
object
elimin
autoantibodi
test
limit
success
small
studi
select
patient
case
report
kramina
et
al
schulz
et
al
direct
pharmacotherapi
rejuven
receptor
success
autoantibodi
target
ident
specif
neurotransmitt
receptor
known
autoantibodi
direct
glutam
system
schizophrenia
best
exemplifi
multitud
studi
examin
nmda
receptor
describ
earlier
hypofunct
receptor
hypothes
mechan
underli
schizophrenia
symptom
presenc
autoantibodi
bind
intern
receptor
lend
support
rational
target
attract
numer
agent
current
avail
known
modul
receptor
promis
research
implic
agent
enhanc
nmda
receptor
function
via
stimul
glycin
modulatori
site
dserin
dcycloserin
bitopertin
although
mix
result
term
treatment
schizophrenia
alberati
et
al
bugarskikirola
et
al
bugarskikirola
et
al
herescolevi
et
al
kantrowitz
et
al
umbricht
et
al
use
immunotherapi
includ
steroid
intraven
immunoglobulin
plasma
exchang
demonstr
promis
improv
symptom
reduct
autoantibodi
case
seri
individu
nmda
receptor
autoantibodyrel
psychosi
find
investig
random
placebocontrol
trial
pharmacolog
strategi
increas
nmda
receptor
function
schizophrenia
wellreview
elsewher
balu
present
evid
support
autoimmun
compon
schizophrenia
context
mechanist
impact
pathway
order
better
understand
formul
novel
treatment
strategi
current
advoc
suggest
compound
replac
antipsychot
new
clinic
trial
examin
safeti
efficaci
adjunct
therapi
care
identifi
individu
demonstr
specif
comorbid
evid
inflamm
need
discuss
context
autoimmun
phenotyp
schizophrenia
number
moieti
potenti
treatabl
immunemodulatori
agent
emerg
includ
pathogen
inflamm
gut
dysbios
effect
autoantibodi
like
combin
approach
may
offer
effect
evalu
adjunct
therapi
exampl
patient
present
gi
symptom
genet
screen
hla
subtyp
coupl
antibodi
studi
might
identifi
subset
patient
would
benefit
approach
treat
celiac
diseas
gluten
intoler
microbiom
screen
fecal
sampl
coupl
blood
test
use
biomark
microbi
dysbios
could
identifi
might
benefit
probiot
gutrel
treatment
genet
screen
complement
deficit
could
identifi
peopl
gene
suscept
might
candid
complement
activ
inhibitionbas
treatment
long
time
treat
schizophrenia
focus
dopamin
sinc
pathway
like
central
physiolog
therapeut
puzzl
schizophrenia
recent
discov
dopamin
particip
signal
immun
cell
similar
manner
synaps
commun
brain
papa
et
al
report
human
special
cell
transfer
dopamin
b
cell
order
boost
product
antibodi
clear
infect
papa
et
al
might
genet
encod
dopamin
defici
contribut
immun
cell
dysfunct
schizophrenia
likewis
could
genet
encod
immun
dysfunct
contribut
dysregul
dopamin
pathway
brain
learn
intric
mechan
govern
immunebrain
interfac
develop
individu
treatment
becom
practic
develop
modal
go
long
way
toward
reduc
enorm
social
econom
cost
associ
schizophrenia
